10 september 2018 - The MS Society has launched a petition imploring the National Institute for Health and Care Excellence, NHS England and Roche to come to an agreement on NHS availability of Ocrevus for primary progressive multiple sclerosis.

The move follow’s the release of final draft guidelines from NICE rejecting Ocrevus (ocrelizumab) - the first ever treatment licensed for PPMS - on grounds that the drug is too expensive for the benefit it provides.

Ocrevus is a first-in-class, humanised monoclonal antibody designed to selectively target CD20-positive B cells, a specific type of immune cell thought to be a key contributor to myelin and axonal (nerve cell) damage, which can lead to disability in people with MS.

Read Pharma Times article